Promising Pharmaceutical Stocks To Research – March 16th

D-Wave Quantum, Eli Lilly and Company, Abbott Laboratories, Merck & Co., Inc., and Johnson & Johnson are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares in companies that research, develop, manufacture, and market medications and healthcare products. These stocks often reflect the industry’s potential for growth through new drug approvals and innovations, but they can also be volatile due to regulatory, clinical, and market-related risks. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

D-Wave Quantum (QBTS)

D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.

D-Wave Quantum stock traded up $3.28 during mid-day trading on Friday, reaching $10.19. The stock had a trading volume of 260,099,071 shares, compared to its average volume of 28,104,618. D-Wave Quantum has a fifty-two week low of $0.75 and a fifty-two week high of $11.41. The stock’s 50-day simple moving average is $6.07 and its 200-day simple moving average is $3.88. The firm has a market capitalization of $2.74 billion, a PE ratio of -24.25 and a beta of 1.12.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Eli Lilly and Company stock traded up $11.90 during mid-day trading on Friday, reaching $813.55. The stock had a trading volume of 3,099,966 shares, compared to its average volume of 3,128,040. The firm has a market capitalization of $771.38 billion, a PE ratio of 69.47, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53. The stock’s 50-day simple moving average is $830.81 and its 200-day simple moving average is $843.24.

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Shares of NYSE:ABT traded down $2.87 during mid-day trading on Friday, hitting $127.02. 9,537,437 shares of the company traded hands, compared to its average volume of 5,533,471. The stock has a market cap of $220.29 billion, a P/E ratio of 16.60, a P/E/G ratio of 2.52 and a beta of 0.70. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The stock has a 50-day moving average price of $127.16 and a two-hundred day moving average price of $119.43.

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of NYSE:MRK traded up $0.01 during mid-day trading on Friday, hitting $94.72. 12,676,238 shares of the company traded hands, compared to its average volume of 9,979,158. The stock has a market cap of $239.27 billion, a P/E ratio of 14.07, a P/E/G ratio of 0.77 and a beta of 0.35. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79. Merck & Co., Inc. has a 12-month low of $81.04 and a 12-month high of $134.63. The stock has a 50-day moving average price of $93.57 and a two-hundred day moving average price of $101.88.

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Johnson & Johnson stock traded down $0.05 during mid-day trading on Friday, reaching $162.94. 6,235,254 shares of the company’s stock were exchanged, compared to its average volume of 7,054,630. The business’s fifty day simple moving average is $154.98 and its 200 day simple moving average is $156.32. The firm has a market capitalization of $392.29 billion, a PE ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.